Market Insight - Big pharma wakes up to the potential of epigenetics
This article was originally published in Scrip
Two significant deals between big pharmaceutical companies and small epigenetic-focused biotechnology firms have been struck in recent weeks, with more expected to follow. Dr Sukaina Virji looks at the companies at the forefront of research into the field of therapeutic epigenetics, the programmes that have caught the eye of big pharma and the potential epigenetics holds for future drug discovery.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.